Boxer Capital, LLC

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
San Diego, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Aaron I. Davis, Chief Executive Officer, Boxer Capital, LLC
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Boxer Capital, LLC

Form 4 holding Other*

Tyra Biosciences, Inc.

Security class
Common Stock
Shares / value
6,448,359
Estimated value
$83,893,151
Report date
06 Feb 2024
Price
$13.01
Ownership
Direct
Form 4 holding Other*

Tango Therapeutics, Inc.

Security class
Common Stock
Shares / value
8,198,642
Estimated value
$68,798,084
Report date
16 Oct 2023
Price
$8.39
Ownership
Direct
Form 4 holding Other*

Tango Therapeutics, Inc.

Security class
Common Stock
Shares / value
6,988,450
Estimated value
$58,642,879
Report date
13 Oct 2023
Price
$8.39
Ownership
Indirect
Form 4 holding Other*

iTeos Therapeutics, Inc.

Security class
Common Stock
Shares / value
2,946,915
Estimated value
$51,571,013
Report date
10 May 2024
Price
$17.50
Ownership
Direct
Form 4 holding Other*

Tango Therapeutics, Inc.

Security class
Prefunded Warrant
Shares / value
2,340,579
Estimated value
$12,053,748
Report date
11 Aug 2023
Price
$5.15
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Tyra Biosciences, Inc.

Security class
Warrant (right to purchase)
Shares / value
705,280
Estimated value
$9,174,988
Report date
06 Feb 2024
Price
$13.01
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Odonate Therapeutics, Inc.

Security class
Common Stock
Shares / value
4,207,086
Estimated value
$6,598,394
Report date
24 Nov 2021
Price
$1.57
Ownership
Direct
Form 4 holding Aaron Davis, the CEO of Boxer Capital, LLC, is a director of Rain Oncology Inc.

Rain Oncology Inc.

Security class
Common Stock
Shares / value
1,152,212
Estimated value
$1,394,177
Report date
22 May 2023
Price
$1.21
Ownership
Direct
Form 4 holding Other*

Tyra Biosciences, Inc.

Security class
Common Stock
Shares / value
85,939
Estimated value
$1,118,066
Report date
06 Feb 2024
Price
$13.01
Ownership
Indirect
Form 4 holding Other*

Mirati Therapeutics, Inc.

Security class
Warrant (right to purchase)
Shares / value
0
Estimated value
Report date
23 Jan 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Other*

Mirati Therapeutics, Inc.

Security class
Warrant (right to purchase)
Shares / value
0
Estimated value
Report date
23 Jan 2024
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Boxer Capital, LLC

4

Rain Oncology Inc.

Report period
22 May 2023
Transactions
1
Transaction value
-$1,243,750
Accepted by SEC
24 May 2023, 20:05
Role
Aaron Davis, the CEO of Boxer Capital, LLC, is a director of Rain Oncology Inc.
Next action
Open filing details
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .